COVID-19 Guidance

UK Myeloma Forum guidance to support medical decision-making in the management of myeloma patients during the COVID-19 (Coronavirus) outbreak

It is clear that the current outbreak is going to impact the ability to deliver healthcare for some months to come. This is especially the case for systemic anti-cancer therapy.

To try and mitigate the impact of changing capacity, and to minimise the risk that the immunosppressive effects of myeloma therapy has, the guidance in the below document has been compiled on 25th March 2020 to help support myeloma doctors in their decision-making and treatment planning.